WEBULL
News
ACOG
5.97
+21.34%
1.05
Weekly Report: what happened at ACOG last week (0202-0206)?
Weekly Report · 1d ago
Weekly Report: what happened at ACOG last week (0126-0130)?
Weekly Report · 02/02 10:24
Weekly Report: what happened at ACOG last week (0119-0123)?
Weekly Report · 01/26 10:24
Weekly Report: what happened at ACOG last week (0112-0116)?
Weekly Report · 01/19 10:30
Biotech Alert: Searches spiking for these stocks today
TipRanks · 01/16 17:10
Alpha Cognition Grants Equity Awards to Executive Team Under 2025 Incentive Plan
Reuters · 01/15 22:28
Weekly Report: what happened at ACOG last week (0105-0109)?
Weekly Report · 01/12 10:29
Alpha Cognition Targets 2,000 ZUNVEYL Prescribers In 2026; Plans 3 Long-Term Care Alzheimer's Studies; Anticipates $3M Asia Licensing Milestone; Aims For Operating Profitability In 2027
Benzinga · 01/07 21:35
Alpha Cognition Announces 2026 Strategy Focused on Expanding ZUNVEYL Prescriber Base, Increasing Long-Term Care Penetration, Initiating New Studies, and Growing International Licensing Opportunities
Reuters · 01/07 21:30
ALPHA COGNITION PROVIDES 2026 CORPORATE UPDATE HIGHLIGHTING STRATEGIC PRIORITIES AND 2025 COMMERCIAL EXECUTION
Reuters · 01/07 21:30
Alpha Cognition Provides 2026 Corporate Update Highlighting Strategic Priorities and 2025 Commercial Execution
Barchart · 01/07 15:30
Weekly Report: what happened at ACOG last week (1229-0102)?
Weekly Report · 01/05 10:23
Weekly Report: what happened at ACOG last week (1222-1226)?
Weekly Report · 12/29/2025 10:22
Weekly Report: what happened at ACOG last week (1215-1219)?
Weekly Report · 12/22/2025 10:22
Alpha Cognition Price Target Maintained With a $18.00/Share by HC Wainwright & Co.
Dow Jones · 12/19/2025 13:09
HC Wainwright & Co. Reiterates Buy on Alpha Cognition, Maintains $18 Price Target
Benzinga · 12/19/2025 12:59
Alpha Cognition: Undervalued ZUNVEYL Growth Story Supports Reiterated Buy Rating and $18 Target
TipRanks · 12/19/2025 11:25
Weekly Report: what happened at ACOG last week (1208-1212)?
Weekly Report · 12/15/2025 10:30
Weekly Report: what happened at ACOG last week (1201-1205)?
Weekly Report · 12/08/2025 10:28
Alpha Cognition CEO Joins Titan Partners Virtual Fireside Chat
Reuters · 12/01/2025 22:51
More
Webull provides a variety of real-time ACOG stock news. You can receive the latest news about Alpha Cognition through multiple platforms. This information may help you make smarter investment decisions.
About ACOG
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.